Table 1. Correlation between relative PAQR3 expression level and clinicopathologic parameters of the patients.
Variables | n | PAQR3 mRNA level | χ2 | ||
---|---|---|---|---|---|
Low | Normal/High | (P-value) | |||
Age (years) | |||||
<50 | 50 | 39 | 11 | 3.270 | |
≥50 | 32 | 19 | 13 | (0.071) | |
Tumor location | |||||
Left | 44 | 31 | 13 | 0.004 | |
Right | 38 | 27 | 11 | (0.953) | |
Tumor size | |||||
≤2 cm | 39 | 27 | 12 | 0.081 | |
>2 cm | 43 | 31 | 12 | (0.776) | |
Differentiation | |||||
Moderate/high | 34 | 11 | 23 | 41.326 | |
Poor | 48 | 47 | 1 | (1.289E-10) | |
T stage | |||||
I/II | 67 | 47 | 20 | 0.060 | |
III/IV | 15 | 11 | 4 | (0.806) | |
Lymph node metastasis | |||||
Negative | 38 | 24 | 14 | 1.962 | |
Positive | 44 | 34 | 10 | (0.161) | |
TNM stage | |||||
I/II | 55 | 35 | 20 | 4.062 | |
III/IV | 27 | 23 | 4 | (0.044) | |
ER status | |||||
Negative | 44 | 30 | 14 | 0.298 | |
Positive | 38 | 28 | 10 | (0.585) | |
Her2 status | |||||
Negative | 29 | 6 | 23 | 54.274 | |
Positive | 53 | 52 | 1 | (1.744E-13) | |
PR status | |||||
Negative | 42 | 35 | 14 | 0.029 | |
Positive | 39 | 23 | 10 | (0.866) |
Note: n, number of patients; ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2; TNM, tumor, node, metastasis. Fisher's exact test was used for statistical analyses. PAQR3 mRNA low expression is defined as tumor/PCHNT < 0.5 and normal/high expression as tumor/PCHNT >= 0.5.